ANTEROGEN CO., LTD.
KOSDAQ-listed stem cell therapy company behind Cupistem for Crohn's fistula and the ALLO-ASC-SHEET pipeline.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2016, Anterogen is a stem cell therapy company. Beyond Cupistem, a Crohn's fistula treatment commercialized in 2012, it holds domestic license-holder rights and exclusive distribution for the pulmonary hypertension drugs Remodulin and Tyvaso, and is developing ALLO-ASC-SHEET for indications including epidermolysis bullosa, diabetic foot ulcers, and burns. In July 2015, it signed a license agreement with Ishin Pharmaceutical of Japan for ALLO-ASC-SHEET covering Japan and Taiwan, valued at a total of USD 75 million (USD 2 million received to date), and the product is currently in Phase 3 trials in Japan for epidermolysis bullosa.
Products & technology
- CupistemCrohn's fistula treatment (adipose-derived stem cell therapy)
- RemodulinPulmonary hypertension treatment
- TyvasoPulmonary hypertension treatment
Regulatory approvals
data.go.kr3 Orphan Drug designations · 2016–2017 / 5 Korean MFDS drug approvals · 2010–2026
- OrphanALLO-ASC-CD2017-02-28Orphan Drug designation · in development20160331806
- OrphanALLO-ASC-CF2017-02-03Orphan Drug designation · in development20160312192
- Orphan힐스템(HEALSTEM) ALLO-ASC-DFU2016-02-23Orphan Drug designation · in development20160015391
- MFDS drugQueencell2026-07-23Drug · Prescription · Approval202602136
- MFDS drugTyvaso (Treprostinil) Inhalation Solution2024-07-05Drug · Prescription · Approval202401656
- MFDS drugCUPISTEM.Inj2021-08-24Drug · Prescription · Approval202106133
- MFDS drugQUEENCELLRevoked2021-06-09Drug · Prescription · Approval202104462
- MFDS drugREMODULIN INJ 1MG/ML, 2.5mg/mL, 5mg/mL, 10mg/mL2010-02-08Drug · Prescription · Approval201001269
Clinical trials
data.go.kr21 MFDS clinical trial authorisations · 2012–2023 (Phase 1 8 · Phase 2 6 · Phase 3 5 · Phase 1/2 2)
- Phase 1ANT-3012023-11-23
1 trial site
- Phase 3ALLO-ASC-DFU2019-05-01
8 trial sites
- Phase 3ALLO-ASC-DFU2019-02-07
4 trial sites
- Phase 3ALLO-ASC-DFU2019-01-04
5 trial sites
- Phase 3ALLO-ASC-DFU2017-07-05
9 trial sites
- Phase 1ALLO-ASC2016-05-09
6 trial sites
- Phase 2ALLO-ASC-DFU2016-05-02
2 trial sites
- Phase 1ALLO-ASC-DFU2016-03-07
1 trial site
- Phase 2ALLO-ASC-DFU2015-12-29
4 trial sites
- Phase 2ALLO-ASC-DFU2015-10-06
2 trial sites
- Phase 1ALLO-ASC-DFU2015-09-21
2 trial sites
- Phase 1ALLO-ASC-DFU2015-09-10
1 trial site
Show 9 more
- Phase 1/2ALLO-ASC-DFU2015-08-26
1 trial site
- Phase 2ALLO-ASC-DFU2015-08-10
4 trial sites
- Phase 2ALLO-ASC2015-05-06
1 trial site
- Phase 1ALLO-ASC-DFU2015-01-13
2 trial sites
- Phase 1ALLO-ASC2014-12-04
6 trial sites
- Phase 1ALLO-ASC-DFU2014-07-04
1 trial site
- Phase 2ALLO-ASC2014-06-02
5 trial sites
- Phase 1/2ALLO-ASC2013-12-16
6 trial sites
- Phase 3큐피스템주(아디포플러스주(ANTG-ASC))2012-06-25
4 trial sites
R&D and key agreements
Source: DART corporate disclosureALLO-ASC-SHEET · 수포성 표피박리증, 당뇨병성 족부궤양, 화상 · 일본 임상 3상 진행중(수포성 표피박리증) · Based on proprietary adipose-derived stem cell technology
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition